Lochs, H. and Adler, G. and Beglinger, C. and Duchmann, R. and Emmrich, J. and Ewe, K. and Gangl, A. and Gasche, C. and Hahn, E. and Hoffmann, P. and Kaskas, B. and Malchow, H. and Pohl, C. and Raedler, A. and Renner, E. and Schoelmerich, Juergen and Schreiber, S. and Stange, E. and Tilg, H. and Vogelsang, H. and Weigert, N. and Zeitz, M. (1999) Anti-TNF antibody in Crohn's disease - status of information, comments and recommendations of an international working group. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 37 (6). pp. 509-512. ISSN 0044-2771,
Full text not available from this repository.Abstract
The chimeric anti-TNF antibody Remicade(R) (Infliximah) has recently been approved for human use by the FDA and is now available on the market, Since there is considerable interest in this kind of treatment among patients with Crohn's disease, an international working group has summarized the presently available information about efficacy side effects and possible problems of this treatment. Studies show that Remicade(R) is effective in the treatment of active Crohn's disease, maintaining remission and fistulae. The working group does not see Infliximab as a first-line treatment for Clohn's disease. It may be used in active phase recurrent disease, chronic active disease and fistulae if standard treatment was not successful. For the surveillance special attention has to be given to the unknown malignancy rate of Infliximab. Infusion should, he performed in an institution, routinely performing intravenous infusions and a two-hour surveillance of the patients should be guaranteed to recognize anaphylactic reactions or acute side effects, There is presently no information indication that the combination with immunosuppressants might increase risks or side effects of this treatment. Due to the limited information available the working group would prefer to use Remicade(R) in studies only and recommends central collection and documentation of all data on efficacy and side effects for the next year.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CA2; anti-TNF antibody; Crohn's disease; chronic inflammatory bowel diseases |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Feb 2023 14:33 |
| Last Modified: | 14 Feb 2023 14:33 |
| URI: | https://pred.uni-regensburg.de/id/eprint/49234 |
Actions (login required)
 |
View Item |
